Medtronic Locks In Permanent U.S. Billing Codes While Racing Toward an October Spinoff Deadline

AMA grants Category I CPT codes to Medtronic's Altaviva and Symplicity Spyral, effective January 2028, as MiniMed exchange offer nears October 9 expiry.

Medtronic has secured a pair of long-sought reimbursement victories that will shape how two of its flagship therapies are paid for in the United States. The American Medical Association has granted Category I CPT codes to the company's implantable tibial neuromodulation device Altaviva and its renal denervation system Symplicity Spyral, replacing the transitional Category III designations both had carried. The new codes take effect in January 2028.

The distinction matters more than the calendar suggests. Category III codes function as temporary placeholders for emerging procedures, while Category I status signals that a therapy has graduated into established medical practice. For a device maker, that shift opens the door to routine hospital and clinic adoption — and the runway to January 2028 gives healthcare providers ample time to fold the new billing pathways into their administrative systems.

Four Clearances in a Single Stretch

Reimbursement is only part of the story. Medtronic's clinical pipeline has produced a string of regulatory wins in quick succession. The FDA handed Breakthrough Device designation to IN.PACT BTK, a drug-coated balloon under development for peripheral arterial disease affecting vessels below the knee. To move toward approval, the company intends to run a randomized trial enrolling roughly 400 patients.

Days earlier, the electrophysiology unit notched its own gains: the Affera Prism-2 mapping software picked up both FDA clearance and the European CE mark, while the PulseSelect ProxBox adapter, paired with proximity-indicator software, also earned CE certification in Europe.

Recognition has arrived from outside the regulatory sphere as well. On September 29, Fortune added Medtronic to its "Change the World" list, citing the Touch Surgery operating-room ecosystem and the Healthy Neighbor program run by Medtronic LABS.

Wall Street Weighs In

Analysts have taken notice of the operational momentum. RBC Capital reaffirmed its Buy rating on Medtronic on October 1, with analyst Kendall Au setting a $118 price target, according to media reports.

The shares responded positively in the latest session, advancing 0.8% to EUR 79.04. Over a seven-day stretch, the stock has added 2.9%. That builds on Monday's move, when the stock closed at EUR 78.44 after a 2.2% gain, putting the company's market capitalization at EUR 98.55 billion. No direct causal link between the FDA's Breakthrough designation and that earlier rally has been established.

The MiniMed Clock Is Running

Offsetting the regulatory tailwinds is a corporate restructuring with a hard deadline attached. Medtronic is pushing ahead with the separation of its diabetes unit, MiniMed — a move that stirred markets just over a week ago and has since delivered a 3.0% gain. But according to a report from Barron's, the exchange offer for MiniMed shares has lost some of its appeal after the stock came under pressure.

The offer covers up to 225,361,295 MiniMed shares and is capped at an exchange ratio of no more than 4.5939 MiniMed shares per Medtronic share. If shareholders balk at the valuation implied by those terms, the separation could stall.

The immediate catalyst is already on the calendar: the exchange offer expires on October 9 unless it is extended or terminated early. The final exchange ratio will be based on volume-weighted average prices from October 5 through October 7. For investors, the outcome of that window is the pivotal marker before attention swings back to clinical programs like IN.PACT BTK.

Pipeline Promise, Pipeline Risk

The roughly 400-patient study for IN.PACT BTK cuts both ways. It represents a substantial commitment of capital and carries the clinical-setback risk inherent to medtech — if the catheter misses its endpoints in testing, the value of prior investment could evaporate. Yet the Breakthrough pathway gives Medtronic closer coordination with regulators and priority review, which shortens development timelines and reduces risk if the trial runs smoothly. Success would open a below-the-knee treatment segment where interventional options remain severely limited.

The same duality applies to the broader portfolio. Should the company execute the MiniMed spinoff in orderly fashion, its focus on higher-margin core businesses would sharpen considerably. Should sentiment around the transaction sour, near-term valuation discounts could weigh on the stock.

For now, the combination of regulatory progress and locked-in long-term reimbursement pathways bolsters Medtronic's position in fiercely competitive markets. The question investors are left to weigh is how quickly the newly cleared products can scale commercially once the billing codes take hold in 2028 — and whether the October 9 deadline passes without derailing the company's restructuring plans.